"Janssen Research & Development is committed to discovering and bringing to market innovative therapeutic solutions for people with brain disorders"
Husseini Manji, M.D., F.R.C.P.C.
Global Head, Neuroscience
The Janssen Research & Development Neuroscience team is focused on neurodegenerative diseases and mood disorders, and we continue our important commercial activities in schizophrenia. While our primary interest is in programs aimed at the discovery and development of novel medicines, we are also interested in new biomarkers and companion diagnostics to drive earlier and more accurate diagnosis, treatment response and outcome prediction in these core focus areas.
We are also interested in biologics and developing novel strategies to address blood-brain barrier challenges to improve central nervous system penetration of large-molecule medicines; for example, through receptor-mediated transcytosis and intra-nasal delivery methods.
To support these disease area interests we are seeking integrative solutions to support the medical rationale of earlier intervention and adherence, and preventing relapse. Examples include non-pharmaceutical cognitive enhancing therapies and remote monitoring technologies.